Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer

Five year pooled data (n = 854) demonstrate a continued survival benefit with nivolumab vs docetaxel, with no new safety signals (overall survival rates 13.4% vs 2.6%; 5-year progression free survival rates 8.0% vs 0%, respectively).

Journal of Clinical Oncology